Who Can Get doxyPEP in England?

doxyPEP means doxycycline post-exposure prophylaxis. Doxycycline is an antibiotic, and in this context it is used after sexual contact rather than as ongoing protection before exposure.

GOV.UK and the UK Health Security Agency define doxyPEP around doxycycline being used within a 24-to-72-hour period after sexual contact. That description explains what the intervention is; it should not be treated as personal dosing advice. Anyone considering doxyPEP should speak to a specialist sexual health service or clinician about whether it is appropriate for them and how it should be used in their circumstances.

The purpose is to reduce the chance of getting some bacterial sexually transmitted infections. In England, however, the public-health focus is particularly on syphilis.

That distinction is important because doxyPEP should not be thought of as a general-purpose method that prevents every STI. GOV.UK specifically states that it does not protect against HIV or viral infections.

Provision in England started in summer 2025 and was rolled out in phases in different regions. Access is through specialist sexual health services rather than as a universal intervention for everyone who is sexually active.

GOV.UK says doxyPEP is offered to people at increased risk of syphilis. This includes some gay and bisexual men and transgender women.

For people assigned female at birth, GOV.UK says doxyPEP is considered on a case-by-case basis where there is an elevated risk of syphilis. This means eligibility is not determined simply by identity or gender. A clinician considers risk and individual circumstances.

The 2025 BASHH UK national guideline on doxyPEP gives more detail about how increased risk can be identified. It recommends offering doxyPEP to people at elevated risk where there has been a recent bacterial STI diagnosis or a recent history of multiple new sexual partners.

BASHH uses a bacterial STI during the previous 12 months, or multiple partners during the previous three months, as indicators that someone may be at higher risk. The guideline covers people aged 16 and over.

These criteria are intended to help clinicians identify people who may benefit; they are not a reason to self-diagnose eligibility. If you think your recent sexual health history may put you at increased risk, the appropriate next step is to contact a sexual health service and discuss it with a clinician.

BASHH also says clinicians may consider doxyPEP on a case-by-case basis for someone at elevated risk of syphilis who attends for care within 72 hours of sexual assault. Anyone who has experienced sexual assault should seek appropriate professional medical and support care.

The central public-health reason for using doxyPEP in England is syphilis prevention.

GOV.UK says doxyPEP is primarily recommended to prevent syphilis because the health risks from untreated syphilis are much more severe. That does not mean doxyPEP makes syphilis impossible to acquire. It is intended to reduce risk rather than provide guaranteed protection.

Its usefulness against gonorrhoea is more limited in England. GOV.UK says doxyPEP is likely to be less effective at preventing gonorrhoea because most circulating strains are already resistant to doxycycline.

This is one reason it is important not to treat doxyPEP as broad STI protection. Someone using doxyPEP can still acquire an infection and still needs the other parts of routine sexual healthcare that are relevant to them.

doxyPEP also does not protect against HIV, and it does not prevent viral infections. It is not a substitute for condoms, testing, vaccination or treatment.

If you are unsure what protection or testing is appropriate for you, a sexual health service can give advice based on your individual circumstances.

Antibiotic resistance is an important part of the discussion around doxyPEP, and UK public-health bodies are monitoring it.

GOV.UK notes that clinical trials have shown varying levels of tetracycline resistance developing in Neisseria gonorrhoeae, the bacterium that causes gonorrhoea, as well as in commensal Neisseria species, Staphylococcus aureus and the gut microbiome.

That concern has to be balanced against the expected benefit of preventing infections in people at elevated risk, particularly syphilis.

GOV.UK also states that no doxycycline resistance has been detected to date in the bacteria that cause syphilis or chlamydia. That does not remove the wider resistance concern, because antibiotic use can affect other bacteria as well.

For gonorrhoea, resistance is already particularly relevant in England because most circulating strains are described by GOV.UK as doxycycline-resistant. This is why doxyPEP is expected to be less effective against gonorrhoea than against syphilis.

Resistance is being followed through existing surveillance, including the Gonococcal Resistance to Antimicrobials Surveillance Programme, or GRASP.

For an individual, the practical point is not to make assumptions about whether the benefits outweigh the risks. That assessment belongs in a conversation with a sexual health clinician, taking account of whether the person is at increased risk and whether doxyPEP is appropriate for them.

doxyPEP is one part of sexual healthcare rather than a replacement for other measures.

GOV.UK is clear that it does not protect against HIV or viral infections. It is also not a substitute for condoms, sexual health testing, vaccination or treatment.

That remains true even for someone who has been offered doxyPEP by a specialist service. Its role is narrower: reducing the risk of some bacterial STIs after sexual contact, with syphilis prevention being the main recommendation in England.

Testing still matters because doxyPEP does not provide complete protection and should not be assumed to rule out an infection. Treatment also remains necessary where an infection is diagnosed.

Similarly, condoms and vaccination have roles that doxyPEP does not replace. The right combination of prevention and testing will depend on the individual, so questions about what is appropriate are best discussed with a sexual health professional.

There is no need to view using one form of protection as a judgement about using another. The aim is simply to match healthcare to a person’s level of risk and needs.

The UK Health Security Agency now includes doxyPEP use in its sexual health reporting for England.

In its sexually transmitted infections quarterly report for England, published on 16 September 2026, UKHSA recorded doxyPEP use at 14,247 consultations during the first quarter of 2026. Those figures were reported by 135 of 219 face-to-face sexual health services, or 62 per cent.

The same UKHSA report recorded 13,529 gonorrhoea diagnoses in the first quarter of 2026, compared with 15,942 in the previous quarter.

It also recorded 1,721 infectious syphilis diagnoses, compared with 1,975 in the previous quarter.

UKHSA cautions that these quarterly numbers are provisional, are likely to be an undercount and should be used to show indicative trends only. They should therefore not be read as complete totals or as proof that any one intervention caused the changes between quarters.

What the reporting does show is that doxyPEP had become part of specialist sexual health provision in England following the phased introduction that began in summer 2025.